Skip to main navigation
Rhythm Pharmaceuticals, Inc. Logo
  • Careers
  • Investors & Media
  • International
  • Search
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Science
    • MC4R Pathway
    • Clinical Focus
    • Research & Development
  • Clinical Trials
  • Patients
    • Disease Focus
  • Product
  • About
    • Our People
    • Leadership
  • Careers
  • Investors & Media
  • International
  • Search
  • Overview
  • Events & Presentations
  • Stock
  • Corporate Governance
  • Financials
    • SEC Filings
    • Quarterly Results
    • Annual Reports
  • News
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact Us

News
September 19, 2022
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022
September 14, 2022
Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering
September 14, 2022
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering
September 7, 2022
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
September 6, 2022
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Granted Marketing Authorization by European Commission for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
September 1, 2022
Rhythm Pharmaceuticals to Present at Investor Conferences in September
August 8, 2022
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
August 3, 2022
Rhythm Pharmaceuticals to Present at Canaccord Genuity 42nd Annual Growth Conference
August 2, 2022
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
July 28, 2022
Rhythm Pharmaceuticals to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
  • First page «
  • Previous page ‹
  • …
  • Page 9
  • Page 10
  • Current page 11
  • Page 12
  • Page 13
  • …
  • Next page ›
  • Last page »
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • California Compliance

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

This website is intended only for residents of the United States.

© 2024, Rhythm Pharmaceuticals, Inc. All Rights Reserved. Rhythm, IMCIVREE, GOLD Academy, LEAD for Rare Obesity, Uncovering Rare Obesity, and their logos are trademarks of Rhythm Pharmaceuticals, Inc.

US-RHY-2400016 05/2024